2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。日前，官网已经公布各项研究摘要题目，本文特将乳腺癌领域重磅研究进展进行汇总，以飨读者。
编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。日前，官网已经公布各项研究摘要题目，本文特将乳腺癌领域重磅研究进展进行汇总，以飨读者。（摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。）
Rapid Oral Abstract Session
Breast Cancer—Metastatic
美国东部时间：5月30日14:45–16:15
北京时间：5月31日03:45–05:15
地点：Hall D2
Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates:A TriNetX real-world evidence study.
使用抗体偶联药物治疗HER2阳性转移性乳腺癌患者的临床效果和种族、民族差异：TriNetX真实世界证据研究
报告时间：14:45–14:51
讲者：Zunairah Shah，MD|Roswell Park Comprehensive Cancer Center
摘要号：1036
Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients’eligibility for HER2-targeted treatment.
使用人工智能辅助软件进行HER2低表达和HER2超低IHC判读培训，以提高病理医师的诊断准确性，并扩大患者接受HER2靶向治疗的资格
报告时间：14:51–14:57
讲者：Marina De Brot，MD，PhD|A.C.Camargo Cancer Center
摘要号：1014
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease:A multi-institution cohort study.
一项多机构队列研究：T-DXd相关间质性肺疾病后治疗再挑战
报告时间：14:57–15:03
讲者：Hope S.Rugo，MD，FASCO|University of California，San Francisco Helen Diller Family Comprehensive Cancer Center
摘要号：1015
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients:Korean Cancer Study Group BR 18-2 MINI trial.
BR 18-2 MINI试验：韩国癌症研究组发起的瑞博西利联合曲妥珠单抗联合内分泌治疗HR+/HER2+晚期乳腺癌患者的IB期和II期研究
报告时间：15:15–15:21
讲者：Joohyuk Sohn，MD，PhD|Division of Medical Oncology，Department of Internal Medicine，Yonsei Cancer Center，Yonsei University College of Medicine
摘要号：1016
HER2-ADC trastuzumab rezetecan(SHR-A1811)in HER2-positive breast cancer with brain metastases:Update results from REIN trial.
HER2-ADC trastuzumab rezetecan（瑞康曲妥珠单抗，SHR-A1811）治疗伴脑转移的HER2阳性乳腺癌：REIN试验的最新结果
报告时间：15:21–15:27
讲者：闫敏（河南省肿瘤医院）
摘要号：1017
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.
阿得贝利单抗联合贝伐珠单抗与顺铂/卡铂治疗三阴性乳腺癌脑转移患者的II期临床研究
报告时间：15:27–15:33
讲者：李婷（复旦大学附属肿瘤医院）
摘要号：1018
Sacituzumab tirumotecan(sac-TMT)as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer(a/mTNBC):Initial results from the phase II OptiTROP-Breast05 study.
II期OptiTROP-Breast05研究的初步结果：Sacituzumab tirumotecan（芦康沙妥珠单抗，sac-TMT）作为不可切除的局部晚期/转移性三阴性乳腺癌（a/mTNBC）的一线治疗
报告时间：15:45–15:51
讲者：殷咏梅（江苏省人民医院）
摘要号：1019
Dose optimization of PF-07248144，a first-in-class KAT6 inhibitor，in patients(pts)with ER+/HER2−metastatic breast cancer(mBC):Results from phase 1 study to support the recommended phase 3 dose(RP3D).
PF-07248144是一种新型KAT6抑制剂，在ER+/HER2−转移性乳腺癌（mBC）患者（pts）中优化PF-07248144的剂量：支持推荐3期剂量（RP3D）的1期研究结果
报告时间：15:51–15:57
讲者：Patricia LoRusso，DO，PhD，FASCO|Yale School of Medicine
摘要号：1020
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies(KM-10A/KCSG BR18-13).
trastuzumab-pkrb联合gedatolisib在2个或更多HER2定向化疗后进展的HER2阳性转移性乳腺癌患者中的2期研究（KM-10A/KCSG BR18-13）
报告时间：15:57–16:03
讲者：KyongHwa Park，MD，PhD|Division of Oncology，Department of Internal Medicine，Korea University Anam Hospital，Korea University College of Medicine
摘要号：1021
Prevention，Risk Reduction，and Genetics
美国东部时间：5月31日08:00-09:30
北京时间：5月31日21:00-22:30
地点：E350|On Demand
Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
接受筛查性乳腺X线摄影的不同女性群体中稳态负荷与乳腺影像组学特征的关联研究
报告时间：08:12-08:18
讲者：Sara Wallam，MD|Columbia University Irving Medical Center
摘要号：10514
Care Delivery and Quality Care
美国东部时间：5月31日08:00-09:30
北京时间：5月31日21:00-22:30
地点：S402
Breast cancer diagnosis，management，and outcomes in transgender，nonbinary，and gender-diverse individuals:A multicenter cohort.
跨性别、非二元性别及性别多样性人群的乳腺癌诊断、管理与预后：一项多中心队列研究
报告时间：08:36-08:42
讲者：Chandler Scott Cortina，MD，MS，FACS|Division of Surgical Oncology，Department of Surgery，Medical College of Wisconsin&MCW Cancer Center
摘要号：1516
Central Nervous System Tumors
美国东部时间：5月31日15:00-16:30
北京时间：6月1日04:00-05:30
地点：S102
Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis:A prospective，single-arm，phase II trial.
优替德隆联合依托泊苷和贝伐珠单抗治疗HER2阴性乳腺癌脑转移患者：一项前瞻性、单臂、II期试验
报告时间：15:00-15:06
讲者：史业辉（天津医科大学肿瘤医院）
摘要号：2012
Breast Cancer—Local/Regional/Adjuvant
美国东部时间：6月1日08:00-09:30
北京时间：6月1日21:00-22:30
地点：Hall B1
NRG-BR003:A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
NRG-BR003：一项随机III期试验，在淋巴结阳性或高危淋巴结阴性TNBC患者中比较了多柔比星+环磷酰胺治疗随后每周接受紫杉醇联合或不联合卡铂治疗的疗效
报告时间：08:00-08:06
讲者：Vicente Valero，MD|The University of Texas MD Anderson Cancer Center
摘要号：LBA509
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin(OC)in comparison to docetaxel/epirubicin/cyclophosphamide(TAC)in patients with early triple-negative breast cancer(TNBC)with homologous recombination deficiency(HRD):Primary results from the ABCSG 45 trial.
前瞻性随机II期ABCSG 45研究的主要结果：在有同源重组缺陷（HRD）的早期三阴性乳腺癌（TNBC）患者中比较奥拉帕利/卡铂（OC）新辅助治疗与多西他赛/表柔比星/环磷酰胺（TAC）的疗效和安全性
报告时间：08:06-08:12
讲者：Christian F.Singer，MD，MPH|Department of Obstetrics and Gynecology and Center for Breast Health，Comprehensive Cancer Center，Medical University of Vienna and
Austrian Breast and Colorectal Cancer Study Group
摘要号：510
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab(SG/P)in patients with early-stage triple-negative breast cancer:Results from the NeoSTAR trial.
在早期三阴性乳腺癌患者中进行的以新辅助治疗反应为导向的戈沙妥珠单抗联合帕博利珠单抗（SG/P）的II期研究：来自NeoSTAR试验的结果
报告时间：08:12-08:18
讲者：Rachel Occhiogrosso Abelman，MD|Massachusetts General Hospital Cancer Center，Harvard Medical School
摘要号：511
The Promise study:A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ.
Promise研究：CE/BZA与安慰剂在绝经后乳腺导管原位癌患者中的术前随机临床试验
报告时间：08:30-08:36
讲者：Swati Kulkarni，MD|Northwestern University Feinberg School of Medicine
摘要号：512
The WinPro trial:A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
WinPro试验：绝经后早期激素受体阳性乳腺癌患者使用和未使用孕激素的内分泌治疗机会窗研究
报告时间：08:36-08:42
讲者：Lucy Haggstrom，MD|St Vincent’s Hospital Sydney and University of New South Wales
摘要号：513
Early results of the French multicenter，randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer:Analysis of toxicity and cosmetic outcomes.
法国多中心、随机SHARE试验的早期结果，比较了全乳房照射与加速部分乳房照射在绝经后早期低风险乳腺癌女性患者中的疗效：毒性和美容结果分析
报告时间：08:42-08:48
讲者：Yazid Belkacemi|AP-HP，Department of Radiation Oncology and Henri Mondor Breast Center，Henri Mondor University Hospital，University of Paris Est Creteil(UPEC)
摘要号：514
Dalpiciclib(Dalp)plus endocrine therapy(ET)as adjuvant treatment for HR+/HER2–early breast cancer(BC):The randomized，phase 3，DAWNA-A trial.
随机、3期DAWNA-A研究：Dalpiciclib（达尔西利，Dalp）联合内分泌治疗（ET）作为HR+/HER2-早期乳腺癌（BC）的辅助治疗
报告时间：09:00-09:06
讲者：邵志敏（复旦大学附属肿瘤医院）
摘要号：515
Efficacy and safety of ribociclib(RIB)+nonsteroidal aromatase inhibitor(NSAI)in NATALEE:Analysis across menopausal status and age.
NATALEE研究中瑞博西利（RIB）联合非甾体芳香化酶抑制剂（NSAI）的疗效与安全性：基于绝经状态和年龄的分层分析
报告时间：09:06-09:12
讲者：Kevin Kalinsky，MD，FASCO，MS|Winship Cancer Institute at Emory University
摘要号：516
The TRADE study:A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2-breast cancer.
TRADE研究：评估早期激素受体阳性/HER2阴性乳腺癌中阿贝西利剂量递增耐受性的II期临床试验
报告时间：09:12-09:18
讲者：Erica L.Mayer，MD，MPH，FASCO|Medical Oncology，Dana-Farber Cancer Institute，Harvard Medical School
摘要号：517
Oral Abstract Session
Breast Cancer—Metastatic
美国东部时间：5月31日13:15-16:15
北京时间：6月1日02:15-05:15
地点：Hall B1
Vepdegestrant，a PROTAC estrogen receptor(ER)degrader，vs fulvestrant in ER-positive/human epidermal growth factor receptor 2(HER2)–negative advanced breast cancer:Results of the global，randomized，phase 3 VERITAC-2 study.
Vepdegestrant[PROTAC雌激素受体（ER）降解剂]vs氟维司群治疗ER阳性/人表皮生长因子受体2（HER2）阴性晚期乳腺癌：全球性、随机、3期VERITAC-2研究的结果
报告时间：13:15-13:27
讲者：Erika P.Hamilton，MD|Breast Cancer Research Program，Sarah Cannon Research Institute
摘要号：LBA1000
Patient-reported outcomes(PROs)in patients with ER+，HER2-advanced breast cancer(ABC)treated with imlunestrant，investigator’s choice standard endocrine therapy，or imlunestrant+abemaciclib:Results from the phase III EMBER-3 trial.
接受imlunestrant或研究者选择的标准内分泌治疗或者imlunestrant+阿贝西利治疗的ER+/HER2-晚期乳腺癌（ABC）患者报告的结局（PROs）：3期EMBER-3研究的结果
报告时间：13:27-13:39
讲者：Giuseppe Curigliano，MD，PhD|Istituto Europeo di Oncologia，IRCCS，University of Milano
摘要号：1001
INAVO120:Phase III trial final overall survival(OS)analysis of first-line inavolisib(INAVO)/placebo(PBO)+palbociclib(PALBO)+fulvestrant(FULV)in patients(pts)with PIK3CA-mutated，hormone receptor-positive(HR+)，HER2-negative(HER2–)，endocrine-resistant advanced breast cancer(aBC).
3期INAVO120试验最终总生存期（OS）分析：inavoisib（伊那利塞，INAVO）/安慰剂（PBO）+哌柏西利（PALBO）+氟维司群（FULV）一线治疗PIK3CA突变的内分泌耐药的HR+/HER2-晚期乳腺癌（aBC）患者
报告时间：14:07-14:19
讲者：Nicholas C.Turner，MD，PhD|Royal Marsden Hospital and Institute of Cancer
摘要号：1003
Phase I/Ib study of inavolisib(INAVO)alone and in combination with endocrine therapy±palbociclib(PALBO)in patients(pts)with PIK3CA-mutated，hormone receptor–positive，HER2-negative locally advanced/metastatic breast cancer(HR+，HER2–LA/mBC):Analysis of hyperglycemia(HG)in prediabetic/obese pts.
inavoisib（INAVO）单独或联合内分泌治疗±哌柏西利（PALBO）治疗PIK3CA突变的HR+/HER2-局部晚期/转移性乳腺癌（LA/mBC）的I/Ib期研究：糖尿病前期/肥胖患者的高血糖（HG）分析
报告时间：14:19-14:31
讲者：Mafalda Oliveira，MD，PhD|Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology(VHIO)
摘要号：1004
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive(ER+)breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor:The CCTG/BCT MA.40/FINER study(NCT04650581).
CCTG/BCT MA.40/FINER研究（NCT04650581）：一项双盲、安慰剂对照的随机、III期临床试验，比较氟维司群和ipatasertib治疗一线CDK4/6抑制剂联合芳香化酶抑制剂治疗进展后的ER+/HER2-晚期乳腺癌
报告时间：14:31-14:43
讲者：Stephen K.L.Chia，MD，FRCPC|BC Cancer Agency
摘要号：LBA1005
Phase III of oral paclitaxel(DHP107)vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer(mBC):Primary analysis of a multinational optimal trial(NCT03315364).
一项III期多国优化试验（NCT03315364）的主要分析：口服紫杉醇（DHP107）与静脉注射紫杉醇治疗HER2阴性复发或转移性乳腺癌（mBC）
报告时间：15:11-15:23
讲者：Sung-Bae Kim，MD|Asan Medical Center，University of Ulsan College of Medicine
摘要号：1007
Exploratory biomarker analysis of trastuzumab deruxtecan(T-DXd)vs physician’s choice of chemotherapy(TPC)in HER2-low/ultralow，hormone receptor–positive(HR+)metastatic breast cancer(mBC)in DESTINY-Breast06(DB-06).
在DESTINY-Breast06（DB-06）研究中，trastuzumab deruxtecan（T-DXd）vs医师选择化疗（TPC）治疗HER2低/超低水平、激素受体阳性（HR+）转移性乳腺癌（mBC）的生物标志物进行探索性分析
报告时间：15:23-15:35
讲者：Rebecca Alexandra Dent，MD，FASCO|National Cancer Centre Singapore
摘要号：1013
Symptom Science and Palliative Care
美国东部时间：6月1日09:45-12:45
北京时间：6月1日22:45-6月2日01:45
地点：S100bc
Randomized control trial to validate mitigation of chemotherapy-induced peripheral neuropathy by limb-cooling apparatus in breast cancer patients receiving paclitaxel(CECILIA).
CECILIA研究：在接受紫杉醇治疗的乳腺癌患者中，验证肢体降温装置减轻化疗诱导的周围神经病变的随机对照试验
报告时间：10:09-10:21
讲者：Toshimi Takano，MD，PhD|Department of Breast Medical Oncology，The Cancer Institute Hospital of Japanese Foundation for Cancer Research
摘要号：12002
Breast Cancer—Local/Regional/Adjuvant
美国东部时间：6月2日15:00-18:00
北京时间：6月3日04:00-07:00
地点：Hall B1
De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer(neoCARHP):A multicentre，open-label，randomised，phase 3 trial.
降阶紫杉类药物联合曲妥珠单抗和帕妥珠单抗±卡铂新辅助治疗HER2阳性早期乳腺癌（neoCARHP）：一项多中心、开放标签、随机、III期试验
报告时间：15:00-15:12
讲者：王坤（广东省人民医院）
摘要号：LBA500
Predicting pathologic complete response(pCR)from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+breast cancer treated with taxane，trastuzumab，and pertuzumab(THP):Secondary results from the EA1181/CompassHER2 pCR trial.
在接受紫杉烷、曲妥珠单抗和帕妥珠单抗（THP）治疗的II/III期HER2+乳腺癌患者中，通过临床病理变量和HER2DX基因组检测预测病理完全缓解（pCR）率：EA1181/CompassHER2 pCR试验的次要结果
报告时间：15:12-15:24
讲者：Nadine M.Tung，MD，FASCO|Beth Israel Deaconess Medical Center
摘要号：501
Prediction of survival after de-escalated neoadjuvant therapy in HER2+early breast cancer:A pooled analysis of three WSG trials.
HER2+早期乳腺癌降阶梯新辅助治疗后的生存预测：三项WSG试验的汇总分析
报告时间：15:24-15:36
讲者：Monika Karla Graeser，MD|West German Study Group and Ev.Hospital Bethesda，Breast Center Niederrhein，Moenchengladbach，Germany and Department of Gynecology，University Medical Center Hamburg
摘要号：502
Comparison of marking techniques for target lymph nodes in 2，596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy:Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study(NCT04373655).
2596例接受新辅助化疗的淋巴结阳性乳腺癌患者目标淋巴结标记技术比较：前瞻性多中心AXSANA/EUBREAST-03/AGO-B-053研究（NCT04373655）的结果
报告时间：16:00-16:12
讲者：Maggie Banys-Paluchowski，PhD|Department of Obstetrics and Gynecology，University Hospital of Schleswig Holstein，Campus Lübeck
摘要号：503
Predicting nodal burden after neoadjuvant chemotherapy(NAC)with circulating tumor(ct)DNA for surgical planning:Results from the I-SPY2 trial.
利用循环肿瘤（ct）DNA预测新辅助化疗（NAC）后的淋巴结负荷用于手术规划：I-SPY2试验的结果
报告时间：16:12-16:24
讲者：Rita Mukhtar，MD|Division of Surgical Oncology，Department of Surgery，University of California，San Francisco
摘要号：504
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer(BC)in the SOFT and TEXT trials assessing benefits from adjuvant exemestane(E)+ovarian function suppression(OFS)or tamoxifen(T)+OFS.
在评估依西美坦（E）+卵巢功能抑制（OFS）或他莫昔芬（T）+OFS辅助治疗获益的SOFT和TEXT试验中，绝经前激素受体阳性早期乳腺癌（BC）女性患者的15年结局
报告时间：16:48-17:00
讲者：Prudence A.Francis，MD，FRACP|Peter MacCallum Cancer Centre
摘要号：505
Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer:Results from the ASTRRA trial.
绝经前激素受体阳性乳腺癌患者接受卵巢功能抑制治疗的最新生存结局和获益预测因素：ASTRRA试验的结果
报告时间：17:00-17:12
讲者：Jai Min Ryu，MD，PhD|Division of Breast Surgery，Department of Surgery，Samsung Medical Center，Sungkyunkwan University School of Medicine
摘要号：506
The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer:Secondary analysis of an international cohort study.
辅助内分泌治疗联合卵巢功能抑制对年轻gBRCA突变携带者乳腺癌生存结局的影响：一项国际队列研究的二次分析
报告时间：17:12-17:24
讲者：Paola Zagami，MD|UNC Lineberger Comprehensive Cancer Center/University of Milan/European institute of Oncology IRCSS(IEO)
摘要号：507
Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy:Phase 3 OASIS 4 trial.
elinzanetant治疗辅助内分泌治疗相关血管舒缩症状的疗效与安全性：III期OASIS 4临床试验
报告时间：17:36-17:48
讲者：Fatima Cardoso，MD|ABC Global Alliance
摘要号：508
Plenary Session
Special Sessions
美国东部时间：6月1日13：00-16:00
北京时间：6月2日02:00-05:00
地点：Arie Crown Theater
Camizestrant+CDK4/6 inhibitor(CDK4/6i)for the treatment of emergent ESR1 mutations during first-line(1L)endocrine-based therapy(ET)and ahead of disease progression in patients(pts)with HR+/HER2–advanced breast cancer(ABC):Phase 3，double-blind ctDNA-guided SERENA-6 trial.
Camizestrant+CDK4/6抑制剂（CDK4/6i）用于HR+/HER2-晚期乳腺癌患者（ABC）一线（1L）内分泌治疗（ET）期间和疾病进展之前出现的ESR1突变：3期、双盲ctDNA指导的SERENA-6试验
报告时间：14:41-14:53
讲者：Nicholas C.Turner，MD，PhD|Royal Marsden Hospital
摘要号：LBA4
Clinical Science Symposium
The Dr.Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation:ctDNA for Breast Cancer:It’s Here—Are We Ready?
美国东部时间：6月1日16:30-18:00
北京时间：6月2日05:30-07:00
地点：Arie Crown Theater
Circulating tumor DNA，pathologic response after neoadjuvant therapy，and survival:First results from TBCRC 040(the PREDICT-DNA trial).
TBCRC 040（PREDICT-DNA试验）的首次结果：循环肿瘤DNA、新辅助治疗后的病理缓解和生存情况
报告时间：16:42-16:54
讲者：Natasha Hunter，MD|University of Washington
摘要号：1009
Circulating tumor(ct)DNA monitoring of ER+/HER2-high-risk breast cancer during adjuvant endocrine therapy.
辅助内分泌治疗期间ER+/HER2-高危乳腺癌的循环肿瘤（ct）DNA监测
报告时间：16:54-17:06
讲者：Lajos Pusztai，MD，PhD，D.Phil，FASCO|Yale Cancer Center，Yale School of Medicine
摘要号：1010
Circulating tumor DNA(ctDNA)dynamics as a predictor of treatment response in metastatic breast cancer(mBC).
动态循环肿瘤DNA（ctDNA）作为转移性乳腺癌（mBC）治疗反应的预测因子
报告时间：17:06-17:18
讲者：Pedram Razavi，MD，PhD|Memorial Sloan Kettering Cancer Center
摘要号：1011
Assessment of ctDNA somatic homologous recombination deficiency(HRD)in triple-negative breast cancer(TNBC)from SWOG S1416 trial.
评估SWOG S1416试验中三阴性乳腺癌（TNBC）患者的ctDNA体细胞同源重组缺陷（HRD）
报告时间：17:18-17:30
讲者：Shane R.Stecklein，MD，PhD|University of Kansas Medical Center
摘要号：1012
Diving Deeper to Inform Hereditary Cancer Risk and Outcomes
美国东部时间：6月2日08:00-09:30
北京时间：6月2日21:00-22:30
地点：S103
Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer:Results from an international cohort study.
BRCA1/2致病性或可能致病性变异类型与年轻乳腺癌患者预后的关系：一项国际队列研究的结果
报告时间：08:00-08：12
讲者：Angela Toss，MD，PhD|University of Modena and Reggio Emilia
摘要号：10509
Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer.
乳腺癌女性患者中癌症易感性基因胚系致病性突变与总生存期的相关性研究
报告时间：08：12-08:24
讲者：Siddhartha Yadav，MD|Mayo Clinic
摘要号：10510
Cancer risk of pathogenic germline variants among 164，774 adult cancers.
在164774例成人癌症患者中，致病性生殖细胞系变异的癌症风险
报告时间：08:48-09:00
讲者：Jie Liu，PhD，MBBS，MPH|Washington University School of Medicine
摘要号：10511
京公网安备 11010502033352号